Business Context and Reporting Period
Company: Healthcare Acquisition Corp. (Note: Input metadata referenced "Altimmune, Inc.", but the filing text identifies the registrant as Healthcare Acquisition Corp., a Delaware corporation).
Reporting Period: Quarterly period ended September 30, 2005 (Inception: April 25, 2005).
Business Model: A "blank check" company (Special Purpose Acquisition Company) formed to acquire an operating business in the healthcare industry. As of the reporting date, the company had not yet consummated a business combination and was in the development stage.
Key Financial Metrics
| Metric | Value (Three Months Ended Sep 30, 2005) | Value (Inception to Sep 30, 2005) |
|---|---|---|
| Total Revenues | $206,261 | $206,261 |
| Net Income | $146,476 | $143,976 |
| Cash and Cash Equivalents | $1,471,369 | $1,471,369 |
| Cash Held in Trust | $68,175,645 | $68,175,645 |
| Total Current Liabilities | $179,118 | $179,118 |
| Stockholders' Equity | $55,964,089 | $55,964,089 |
| Net Income Per Share (Basic/Diluted) | $0.02 | $0.03 |
Liquidity: The company holds approximately $68.2 million in a trust fund invested in U.S. Treasury Bills or money market funds. Approximately $1.5 million is held outside the trust for working capital.
Material Changes and IPO Activity
- Initial Public Offering (IPO): Consummated on August 3, 2005, with an additional 400,000 units sold on August 16, 2005 via over-allotment. Total gross proceeds were $75,200,000.
- Net Proceeds: Approximately $69,450,000 after deducting underwriting discounts ($4,512,000) and offering expenses ($1,220,000).
- Trust Fund: $67,928,000 (90.3% of gross proceeds) was deposited into an interest-bearing trust account to fund a potential redemption or liquidation.
- Revenue Source: All revenue is derived from interest and dividends earned on the trust fund ($189,914 interest + $8,227 dividends).
- Expenses: Total expenses for the period were $49,785, primarily consisting of management fees, insurance, and travel.
Outlook, Risks, and Management Commentary
- Business Combination Deadline: The company must consummate a business combination within 18 months of the IPO (by February 2007), or 24 months if extension criteria are met. Failure to do so triggers mandatory liquidation.
- Target Criteria: The first business combination must be with a target having a fair market value of at least 80% of the company's net asset value (excluding trust cash and deferred underwriting fees).
- Redemption Rights: Public stockholders may redeem their shares for a pro-rata share of the trust fund if they vote against a business combination. Approximately 19.99% of the trust fund ($13,578,807) is classified as "common stock subject to possible redemption."
- Capital Sufficiency: Management believes the $1.5 million held outside the trust is sufficient to operate through July 31, 2007, assuming no business combination is consummated.
- Risks: No assurance exists that a business combination will be completed. The trust fund may be subject to third-party claims despite waivers. The company has no current operations other than the search for a target.
- Subsequent Event: In October 2005, the trust agreement was amended to allow investment in money market funds to reduce tax liability.
Investor Verification Checklist
- Verify the status of the 18-month deadline for consummating a business combination.
- Confirm the current balance of the trust fund and any withdrawals made for taxes or working capital.
- Review the terms of the "Purchase Option" granted to the underwriter (225,000 units at $10/unit) and its potential dilution impact.
- Monitor the $7,500 monthly fee arrangement with affiliates (Equity Dynamics, Inc. and The Lan Group) for office space and services.
- Check for any announcements regarding the identification of a target business in the healthcare sector.